NY-IFF
IFF (NYSE:IFF) has released its 2021 environmental, social and governance plus sustainable solutions (or ESG+) performance report. Published today, “Transforming Our World ,” details the Company’s commitment to do more good for people and the planet, aligned with IFF’s purpose—Applying science and creativity for a better world. Centered around the recently launched Do More Good Plan , the report updates progress on legacy IFF targets, looks ahead to even more ambitious 2030 objectives, and aims to address the world’s most pressing sustainable development challenges from IFF’s perspective.
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET.
“At IFF, we’re taking a holistic approach to creating a better world by leveraging our business, performance and partners,” said Frank Clyburn, IFF CEO. “Since the launch of our first sustainability program in 2010, we’ve made tremendous progress. To continue driving results, we’re challenging our teams to be accountable, to collaborate across divisions, and to execute on our ESG+ strategy.”
“At today’s IFF, we’re taking another bold step, embedding a more comprehensive ESG structure in every part of our business, including the solutions we produce to help our customers reach their own ESG goals,” Mr. Clyburn continued. “Following the merger with DuPont’s Nutrition and Biosciences division, this report showcases our first year of results since launching our Do More Good Plan. We’re proud of the many ways we’re becoming a stronger, more resilient company, as we apply science and creativity for a better world.”
The 2021 ESG+ Report aligns with the Do More Good Plan’s four pillars: Sustainable Solutions, Climate and Planetary Health, Equity and Wellbeing, and Transparency & Accountability.
Examples of 2021 performance highlights and achievements include:
- Recognized for ESG leadership: named to the Dow Jones Sustainability Indices for the second consecutive year, received the EcoVadis platinum sustainability rating, and included in the Bloomberg Gender Equality Index
- Enabled and accelerated the wider adoption of sustainable solutions in the marketplace across divisions, and promoted circular economy growth through IFF products verified as Upcycled Certified™
- Continued commitment to climate action—being one of only 14 companies out of nearly 12,000 assessed—named by CDP as a triple A list company for corporate transparency on climate change, water stewardship and deforestation
- Strengthened commitment to diversity, equity and inclusion, honored by the Human Rights Campaign as a Best Place to Work for LGBTQ Equality for the third consecutive year, and named among the Best Places to Work for Disability Inclusion by Disability:IN for the second consecutive year
To read IFF’s 2021 ESG+ Report, click here or visit: https://www.iff.com/responsibilities/strategy-reporting/report-library .
Webcast
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ metrics and performance results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET. Mr. Clyburn will be joined by Michael DeVeau, Chief Investor Relations & Communications Officer; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Pete Sommers, Interim Chief Human Resources and Diversity, Equity & Inclusion Officer; and Kip Cleverley, Vice President, Global Sustainability & EHS. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .
Investors and analysts are invited to participate by phone by calling 866-342-8591 from the United States and 203-518-9713 from other locations. The access code for the conference call is IFF0609. A live listen-only webcast will also be available at ir.iff.com . For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF)—an industry leader in food, beverage, scent, health and biosciences—science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom